Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 127

Results For "market"

3606 News Found

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
Clinical Trials | July 16, 2024

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain


Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Drug Approval | July 14, 2024

Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial

Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension


Thermo Fisher Scientific completes acquisition of proteomics solutions company ‘Olink’
News | July 14, 2024

Thermo Fisher Scientific completes acquisition of proteomics solutions company ‘Olink’

Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine


Health Minister Nadda reviews Ayushman Bharat PMJAY and Ayushman Bharat Digital Mission
Policy | July 14, 2024

Health Minister Nadda reviews Ayushman Bharat PMJAY and Ayushman Bharat Digital Mission

Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states


KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag
Healthcare | July 10, 2024

KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag

KIMS already have a multi-specialty hospital and gastro unit at Vizag


Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Drug Approval | July 10, 2024

Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%

The approved ANDA is therapeutically equivalent to the reference listed drug product


Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
Drug Approval | July 10, 2024

Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets

Sacubitril and Valsartan combination is used to treat chronic heart failure in adults


Zydus receives tentative approval from USFDA for Diroximel Fumarate DR Capsules
Drug Approval | July 10, 2024

Zydus receives tentative approval from USFDA for Diroximel Fumarate DR Capsules

Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis


Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets
Drug Approval | July 10, 2024

Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets

This product will be manufactured at Lupin’s Pithampur facility in India


Ligand to acquire Apeiron Biologics for US$100 million
News | July 09, 2024

Ligand to acquire Apeiron Biologics for US$100 million

Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.